St. Louis - General Offices

June 21, 1965

Pydraul 312 Technical Bulletin

Your Memo 6/15/65

Larry Bradford
LBRAD

R. Davis/D. Smith
C. L. Early CEARL
L. G. Farron LFARR
P. G. Ziegenfuss PZIEG

I would re-word the 3rd paragraph on page 14 which relates to vapor inhalation hazards as follows:

> "At room temperature there is no significant vapor inhalation hazard from Pydraul 312; however, inhalation of vapors produced when the fluid is at high temperatures should be prevented. Single 6-hour exposures to an atmosphere saturated with vapors at ambient temperatures produced only mild discomfort in experimental animals and they survived the 10-day subsequent observation period without ill effect."

The last line of the 4th paragraph should be re-worded to avoid the use of the trade name "Pontocaine." This sentence should read: "To relieve irritation physicians have used 1% tetracaine solutions, as well as opthalmic cortisone acetate solution."

Elmer P. Wheeler

EPW:mjb